Video Series

Jeffrey Matous, MD, leads a panel discussion surrounding the use of bispecifics treatment of relapsed / refractory multiple myeloma.

Key opinion leaders navigate diagnostic challenges associated with atopic dermatitis.

Casey Butrus, PharmD, leads a panel of experts in a discussion surrounding atopic dermatitis.

Dr Lopes provides insights into payer considerations when navigating geographic atrophy treatment pathways.

Drs Lally and Khanani expand on key takeaways from the GATHER1 and GATHER2 studies.

Dr Michos examines a controlled trial focusing on co-payment elimination and its effects on cardiovascular outcomes for low-income adults.

In his closing thoughts, Dr Marshall shares final takeaways from the 2023 ASCO GI Cancers Symposium.

The GATHER1 and GATHER2 studies are highlighted.

Medical experts recap the DERBY and OAKS studies.

The SPOTLIGHT study results presented at the 2023 ASCO GI Cancers Symposium are explored by Dr Marshall.

Dr Michos offers strategies to successfully reduce LDL levels in patients with cardiovascular disease.

GA treatment options in various steps in FDA approval process are discussed by a panel of medical experts.

Maria Lopes, MD, MS, highlights the utilization of health care resources to optimize GA treatment impact.

Dr Marshall shares insights directed at the use of real-world evidence [RWE] and its impact on unmet needs in colorectal cancer [CRC] treatment.

Erin Michos, MD, MHS, opens a discussion surrounding the utilization of bempedoic acid for patients with intolerance to statin-based therapies.

Dr Haumschild leads a discussion surrounding comorbidities associated with geographic atrophy.

David Lally, MD, highlights risk factors associated with geographic atrophy.

In their closing thoughts, the expert panelists discuss the future of the disease state and treatment options, and how they expect provider, patient, and payer value perception to change in the future.

The panelists discuss how payers can best engage with the retinal disease community on a provider and patient level.

Panelists provide their closing thoughts on the disease state and treatment landscape of multidrug-resistant HIV.

Dr Lopes and Mr Driffin discuss cost considerations and utilization barriers inhibiting treatment for patients with multidrug-resistant HIV.

Maria Lopes, MD, MS, and Mr Driffin explore total cost of care affected by various multidrug-resistant treatment regimens.

A medical expert discusses real-world analyses surrounding the use of ctDNA.

Geographic atrophy disease progression is explored by a panel of medical experts.

Ryan Haumschild, PharmD, MS, MBA, opens a discussion surrounding the disease landscape of geographic atrophy.

Dr Sheth discusses the evolution of access to treatment for AMD/DME over the past few years and initiatives to expand treatment access.

Joseph Coney, MD, FASRS, FACS, discusses switching anti-VEGF agents in the treatment of wet AMD and what payers should consider when switching anti-VEGF therapies.

Daniel Driffin, BS, MPH, provides insights regarding factors influencing patient adherence to multidrug-resistant HIV treatment.